False positive seroreactivity to brucellosis in tuberculosis patients: a prevalence study by Varshochi, Mojtaba et al.
© 2011 Varshochi et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of General Medicine 2011:4 207–210
International Journal of General Medicine Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
207
OrIGInAL reseArch
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/IJGM.S15120
False positive seroreactivity to brucellosis  
in tuberculosis patients: a prevalence study
Mojtaba Varshochi1,2
Jafar Majidi2
Marjan Amini1
Kamyar Ghabili3
Mohammadali M shoja3
1Department of Infectious Disease, 
Tabriz University of Medical 
sciences, Tabriz, Iran; 2Infectious 
Disease and Tropical Medicine 
research center, Tabriz University 
of Medical sciences, Tabriz, Iran; 
3Tuberculosis and Lung Disease 
research center, Tabriz University  
of Medical sciences, Tabriz, Iran
correspondence: Mohammadali M shoja 
Tuberculosis and Lung Disease  
research center, Tabriz University  
of Medical sciences, Tabriz, Iran 
Tel/Fax +98 411 4438523 
email shoja.m@gmail.com
Background: The rising worldwide incidence of tuberculosis (TB) increases the demand for 
knowledge about its potential seroreactivity with other microbial agents. A few reports and 
the authors’ experiences indicate that tuberculosis may result in a false-positive brucellosis 
serology. This may cause a diagnostic challenge because of the close clinical resemblance of 
these two infections.
Objective: The aim of the present prevalence study was to elucidate brucellosis seroreactivity 
in patients with active TB.
Methods: Ninety-eight patients with newly diagnosed and active TB were studied using an 
enzyme-linked immunosorbent assay (ELISA) and Wright’s and Coombs–Wright’s tests. 
Seventy-five healthy individuals were used as controls. The patients showed signs of   recovery 
after starting a standard anti-TB regimen and had no clinical evidence of brucellosis at a 
  subsequent 6-month follow-up. The data were analyzed statistically by Fisher’s exact test using 
SPSS 11.0.
Results: We found that 9.2% of TB patients versus 1.3% of healthy controls had positive results 
on the anti-Brucella IgG ELISA (P = 0.04). Five TB patients were found to have agglutination 
on Wright’s tests, while none of the controls showed agglutination.
Conclusion: Active TB patients may have some seroreactivity with Brucella antigens, and 
Brucella IgG ELISA may give a false positive in these patients. Clinicians should consider false 
positive brucellosis seroreactivity in patients with active TB.
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Introduction
Brucellosis and tuberculosis (TB) are two important public health hazards of   particular 
concern in developing countries and the Middle East.1 These two infectious diseases 
have some overlapping clinical features; hence, diagnosis relies mainly on para-
clinical studies. Brucellosis serological tests are reported to have high sensitivity.2,3 
However, their specificity is limited by antigenic cross-reactivity and the false posi-
tive results encountered in infections with Salmonella, Francisella, Vibrio cholerae, 
Yersinia enterocolitica, Serratia marcescens, Haemophilus influenzae, Pseudomonas 
aeruginosa, group A beta-hemolytic Streptococci and Escherichia coli, and the malaria 
parasite.1,2,4–9 The specificity of these serological tests is particularly important during 
a program of Brucella eradication.4
The Centers for Disease Control and Prevention has reported a false-positive 
  Brucella antibody assay in a patient with constitutional symptoms mimicking 
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can be serious, clinicians and public health professionals 
should have a thorough knowledge of Brucella serological 
  cross-reactions. Anecdotally, we have had several patients 
with features of spinal osteomyelitis, vertebral collapse 
and fever of unknown origin, in whom the initial sero-
logical   studies showed a considerable titer of anti-Brucella 
  antibodies. However, those patients showed no clinical 
improvement with Brucella chemotherapy, and surprisingly, 
later investigations yielded a diagnosis of TB. The literature 
describes other cases of the involvement of brucellosis, TB, 
or both in spinal infection,1,10 and in other conditions such 
as meningitis11 and primary peritonitis,12 as well as fevers 
of unknown origin.13
With the increasing worldwide incidence of TB, in 
the era of human immunodeficiency (HIV) infection, 
  knowledge about potential seroreactivity associated with 
TB may be of paramount diagnostic value. The aim of this 
study was to evaluate false-positive brucellosis seroreactivity 
detected by enzyme-linked immunosorbent assay (ELISA), 
Wright’s or standard tube agglutination (STA) tests, and 
  Coombs–Wright’s tests in patients with active TB.
Methods
Patient selection
The prevalence study included 98 consecutive patients with 
newly diagnosed TB referred to a university-affiliated center, 
the Tuberculosis and Lung Disease Research   Center, between 
April 2003 and July 2004. Informed consent was obtained 
from the patients ahead of the study. All the patients had 
a bacteriological (acid-fast bacilli [AFB] smear plus culture) 
or histopathological (for some forms of extrapulmonary TB) 
diagnosis of TB. Exclusion criteria were age less than 12 years, 
past history of brucellosis or a known malignancy, intravenous 
drug abuse, HIV infection, and exposure to domestic animals or 
their products. Age, gender, clinical   category of TB (pulmonary 
versus   extrapulmonary; Table 1), the clinically symptomatic 
period, and purified protein derivative test results were recorded 
for each patient. An age- and sex-matched control group of 75 
healthy individuals without history of brucellosis, tuberculosis, 
or any systemic disease was recruited during the same period 
from potential kidney donors referred to the central university 
hospital for examination. The institutional board review and 
ethics   committee approved the protocol.
Blood collection and analysis
A 5 mL venous blood sample was drawn from each patient. 
Serum was separated by centrifugation at 750 × g for 
10   minutes at room temperature and was then stored at −20°C 
pending analysis. All the serum samples were analyzed 
for anti-Brucella antibodies by ELISA and Wright’s test. 
A Coombs–Wright’s test was also performed if agglutination 
was seen on Wright’s test, as well as randomly in 18 patients 
who had negative Wright’s tests.
A Brucella IgG ELISA kit (IBL, Hamburg, Germany) 
was used to titrate the serum anti-Brucella IgG as described 
by Cox.14 Briefly, 1 µL of serum was diluted 1:101, and after 
buffer-washing, 100 µL of horseradish peroxidase-conjugated 
anti-human IgG was added. The mixture was incubated for 
30 minutes at room temperature and was then treated with 
tetramethyl benzidine (TMB) for 20 minutes. A Brucella 
antibody-antigen reaction was indicated by a blue coloration. 
Subsequently, a TMB stop solution was added, and the optical 
density of the well was measured with a spectrophotometer 
(Stat Fax 3200, Awareness Technology, Inc., Palm City, FL, 
USA); at 450 nm. A serum titer of more than 12 U/mL was 
considered positive.
The Wright’s test was performed according to Edwards 
et al.15 Briefly, 1 mL doubling dilutions of serum were 
made, beginning with a dilution of 1:40. A 0.05 mL aliquot 
of concentrated Brucella antigen (Pasteur Institute, Tehran, 
Iran) was added to each diluted sample. The titer of the 
serum was recorded as the last tube showing agglutination 
readily visible to the naked eye after gentle shaking. For the 
Coombs–Wright’s test, the tubes that were negative on the 
Wright’s test were centrifuged, and the pellets were washed. 
After adding a drop of anti-human globulin (Coombs reagent; 
Cinagen, Tehran, Iran), the tubes were incubated at 37°C 
for 30 minutes. Agglutination was assessed after a final 
  centrifugation and was quantified as the last positive tube.
Data analysis
All data were presented as mean ± standard deviation. The 
data were analyzed statistically by Fisher’s exact test using 
Table 1 clinical features of TB patients with reference to their 
brucellosis serorectivity
All patients (n) Patients with false 
positive ELISA (n)
Pulmonary TB 83 7
cervical adenitis 8 1
renal TB 2 0
Lupus vulgaris 1 0
Genitourinary TB 3 0
Intestinal TB 1 0
Pleuritis 1 1
Peritonitis 1 0
Note: Two patients had concomitant TB of two organs.
Abbreviations: eLIsA, enzyme-linked immunosorbent assay; TB, tuberculosis.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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SPSS software (v. 11.0; SPSS Inc, Chicago, IL). A P value 
less than 0.05 was considered statistically significant.
Results
The mean age of the patients was 50.8 ± 19.7 years 
(range 14–84). There were 45 (46%) female and 53 (54%) 
male patients. Eighty-five percent of the patients had 
  pulmonary TB and 15% had extrapulmonary TB. The mean 
period during which the patients had been symptomatic was 
217.5 days. Table 1 details the clinical features of the TB 
patients enrolled in this study.
Nine TB patients (9.2%) and one healthy control (1.3%) 
gave positive results on the anti-Brucella IgG ELISA 
  (two-tailed P = 0.044). Five of the TB patients, but none 
of the healthy controls, showed agglutination on Wright’s 
test. The Wright’s agglutinin titer ranged between 1:40 and 
1:80. The Coombs–Wright’s test titers ranged between 1:80 
and 1:160 for those patients who had shown agglutination 
on Wright’s test. None of the 18 random samples showed 
agglutination on the Coombs–Wright’s test.
Discussion
The present study revealed that the anti-Brucella IgG 
ELISA gave a significant false-positive rate in active TB 
patients. The Brucella ELISA test is generally believed 
to have a higher sensitivity and specificity in determining 
  Brucella-specific antibodies than other serological tests.2,16–21 
  Memish et al compared the standard tube agglutination test 
and ELISA results in brucellosis patients, and in contrast to 
the above-referenced studies, reported that the sensitivity and 
specificity of ELISA IgG (45.6% and 97.1%, respectively) 
were lower than those of the standard tube agglutination 
test (95.6% and 100.0%, respectively).22 Cakan et al found 
that the ELISA test for brucellosis was more sensitive when 
both IgG and IgM were used, but the titer value alone did 
not represent disease status.23
In the present study, 5 out of 98 TB patients showed 
agglutination on the standard tube agglutination test. Only 
one patient had a significant positive (1:160) titer for an 
endemic area. However, the low titers (1:40–1:80) of 
the standard tube agglutination test might be important 
in relation to   cross-reactivity. Yildiz et al found cross-
reactivity of the   standard tube agglutination tests with other 
bacterial infections including Salmonella, Streptococci, 
and Escherichia coli, but none of their four TB patients 
showed brucellosis seroreactivity.5 The authors concluded 
that the results of the standard tube agglutination test 
should be interpreted   according to the local endemicity 
and   seropositivity rate of the   population. Mert et al also 
found no   false-positive   standard tube   agglutination results 
in 20 patients with miliary TB.2 In the study of Cetin et al, 
  antibodies for   Brucella were reported in 1.8% of the normal 
population, 6% of high-risk   individuals, and 6.7% of patients 
with Brucella-related complaints.24 In the present study, only 
1.3% of the healthy individuals had a positive antibody titer 
on the Brucella ELISA. Likewise, previous studies have 
revealed a ∼3% of seroprevalence for brucellosis in the 
general   population of Iran.25,26
The diagnosis of brucellosis relies mostly on the results 
of serological tests in patients with suggestive history and 
physical findings. Most farming areas in Iran are endemic 
for brucellosis. Therefore, in clinical practice, Wright’s test 
titers of 1:160 or greater are generally considered positive if 
the patient is from an endemic region. In the present study, 
none of the TB patients had a Wright’s test titer equal to or 
greater than 1:160. However, it should be noted that a low 
titer serology might warrant significance in patients with a 
spectrum of constitutional symptoms resembling brucellosis 
and TB. A Coombs–Wright’s test titer of 1:160 was encoun-
tered in one patient. Although we did not perform a blood or 
bone marrow culture for brucellosis, a 6-month follow-up 
showed that all these patients responded dramatically to the 
World Health Organization (WHO) standard antitubercu-
losis regimen, and none of them developed symptoms or 
signs suggestive of brucellosis. Moreover, Brucella blood 
cultures are reportedly positive in 15%–35% of patients 
with active disease.18 We therefore thought that adding this 
expensive and time-consuming test to the present study 
would not enhance our results. Polymerase chain reaction 
(PCR) methods have been developed, and these distinguish 
clearly between brucellosis and TB infections, but they are 
also likely to prove expensive and would require thorough 
training in the relevant technical skills, which may limit their 
general applicability.27,28
Ultimately, active TB patients may show some sero-
reactivity to Brucella antigens and a Brucella IgG ELISA 
may be falsely positive in these patients. Clinicians should 
consider these cross-reactions when interpreting the results 
of serological tests in TB patients. Future studies with larger 
numbers of patients and further investigations including 
culture of the bacteria or PCR are required to clarify the 
issue further.
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